Brian G. Hockley

ORCID: 0000-0003-4112-4299
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Medical Imaging Techniques and Applications
  • Radiopharmaceutical Chemistry and Applications
  • Neuroscience and Neuropharmacology Research
  • Chemical Reactions and Isotopes
  • Fluorine in Organic Chemistry
  • Nicotinic Acetylcholine Receptors Study
  • Advanced MRI Techniques and Applications
  • Inhalation and Respiratory Drug Delivery
  • Pharmacological Effects and Assays
  • Blood donation and transfusion practices
  • Asthma and respiratory diseases
  • Radioactive element chemistry and processing
  • Urinary Tract Infections Management
  • Lanthanide and Transition Metal Complexes
  • Chemical Synthesis and Characterization
  • Pediatric Urology and Nephrology Studies
  • Lung Cancer Treatments and Mutations
  • Cancer, Hypoxia, and Metabolism
  • Prostate Cancer Treatment and Research
  • Pharmacological Receptor Mechanisms and Effects
  • Parkinson's Disease Mechanisms and Treatments
  • Trauma, Hemostasis, Coagulopathy, Resuscitation
  • Blood transfusion and management
  • Peptidase Inhibition and Analysis
  • Liver Disease and Transplantation

University of Michigan
2013-2024

NHS Blood and Transplant
2014-2018

Ann Arbor Center for Independent Living
2015

Michigan Medicine
2009

University of East Anglia
2002

Sheffield Health and Social Care NHS Foundation Trust
2001

North Middlesex Hospital
1985

Middlesex Hospital
1983

Abstract The field of radiochemistry is moving toward exclusive use automated synthesis modules for production clinical radiopharmaceutical doses. Such a move comes with many advantages, but also presents radiochemists the challenge re‐configuring radiopharmaceuticals that require nonconventional while maintaining full automation. This review showcases versatility Tracerlab FX FN module by presenting simple, fully methods producing [ 18 F]FLT, F]FAZA, F]MPPF, F]FEOBV, F]sodium fluoride,...

10.1002/jlcr.1865 article EN Journal of Labelled Compounds and Radiopharmaceuticals 2011-02-21

Abnormally aggregated tau is the hallmark pathology of tauopathy neurodegenerative disorders and a target for development both diagnostic tools therapeutic strategies across disease spectrum. Development carbon-11- or fluorine-18-labeled radiotracers with appropriate affinity specificity would allow noninvasive quantification burden using positron emission tomography (PET) imaging. We have synthesized [(18)F]lansoprazole, [(11)C]N-methyl lansoprazole, [(18)F]N-methyl lansoprazole identified...

10.1021/cn500103u article EN publisher-specific-oa ACS Chemical Neuroscience 2014-06-04

Abstract Purpose To optimize the direct production of 68 Ga on a cyclotron, via Zn(p,n) reaction using liquid cyclotron target. We Investigated yield cyclotron-produced Ga, extraction [ Ga]GaCl 3 and subsequent Ga]Ga-PSMA-11 labeling an automated synthesis module. Methods Irradiations 1.0 M solution Zn]Zn(NO ) 2 in dilute (0.2–0.3 M) HNO were conducted GE PETtrace cyclotrons targets. The proton beam energy was degraded to nominal 14.3 MeV minimize co-production 67 through Zn(p,2n) without...

10.1186/s41181-020-00106-9 article EN cc-by EJNMMI Radiopharmacy and Chemistry 2020-11-12

Abstract Background Nuclear medicine has made enormous progress in the past decades. However, there are still significant inequalities patient access among different countries, which could be mitigated by improving to and availability of radiopharmaceuticals. Main body This paper summarises major considerations for a suitable pharmaceutical regulatory framework facilitate These include distinct characteristics radiopharmaceuticals require dedicated regulations, considering impact variable...

10.1186/s41181-023-00230-2 article EN cc-by EJNMMI Radiopharmacy and Chemistry 2024-01-02

Cirrhosis is a complex acquired disorder of coagulation and frequent indication for transfusion blood components. We characterised component use in patients with cirrhosis compared this to guidelines.All National Health Service trusts representation on the British Society Gastroenterology membership list were invited take part. Data collected prospectively consecutive, unselected, hospitalised admissions over 28 days. Detailed information was recorded receiving components including (for...

10.1111/liv.12999 article EN Liver International 2015-11-05

The field of radiochemistry is moving toward exclusive use automated synthesis modules for production clinical radiopharmaceutical doses. Such a move not only comes with many advantages but also presents radiochemists the challenge re‐configuring radiopharmaceuticals that require non‐conventional while maintaining full automation. Herein, we continue our series articles showcasing versatility Tracerlab FX by presenting straightforward, fully methods preparing range carbon‐11 labeled using...

10.1002/jlcr.1937 article EN Journal of Labelled Compounds and Radiopharmaceuticals 2011-10-20

Green strategies for late-stage fluorination with <sup>18</sup>F, in which ethanol and water are the only solvents used throughout entire radiolabeling process, have been developed applied to radiosyntheses of a range radiopharmaceuticals commonly employed clinical PET imaging.

10.1039/c5cc05919d article EN Chemical Communications 2015-01-01

Abstract Background In the US, EU and elsewhere, basic clinical research studies with positron emission tomography (PET) radiotracers that are generally recognized as safe effective (GRASE) can often be conducted under institutional approval. For example, in United States, such is oversight of a Radioactive Drug Research Committee (RDRC) long certain requirements met. Firstly, must for science cannot intended immediate therapeutic or diagnostic purposes, to determine safety effectiveness PET...

10.1186/s41181-020-00110-z article EN cc-by EJNMMI Radiopharmacy and Chemistry 2020-11-11

[ 11 C]Carfentanil ([ C]CFN) is a selective radiotracer for in vivo positron emission tomography imaging studies of the μ‐opioid system that, our laboratories, synthesized by methylation corresponding carboxylate precursor with C]MeOTf, and purified using C2 solid‐phase extraction cartridge. Changes commercial availability common cartridges have necessitated future proofing synthesis C]CFN to maintain reliable delivery clinical studies. An updated reported that replaces now obsolete...

10.1002/jlcr.3513 article EN Journal of Labelled Compounds and Radiopharmaceuticals 2017-04-17

[18F]AV1451 is a commonly used radiotracer for imaging tau deposits in Alzheimer's disease (AD) and related non-AD tauopathies. Existing radiosyntheses of require complex purifications to provide doses suitable use clinical studies. To address this issue, we have modified the synthesis only 0.5 mg precursor, optimized Boc-deprotection step developed simplified method HPLC purification radiotracer. An using TRACERLab FXFN module led high radiochemical yield (202 ± 57 mCi per synthesis) with...

10.1186/s41181-017-0027-7 article EN cc-by EJNMMI Radiopharmacy and Chemistry 2017-06-06

(-)-[(18) F]Flubatine was selected for clinical imaging of α4 β2 nicotinic acetylcholine receptors because its high affinity and appropriate kinetic profile. A fully automated synthesis F]flubatine as a sterile isotonic solution suitable use is reported, well the first evaluation in nonhuman primates (rhesus macaques). prepared by fluorination Boc-protected trimethylammonium iodide precursor with [(18) F]fluoride an module. Subsequent deprotection Boc group 1-M HCl yielded F]flubatine, which...

10.1002/jlcr.3069 article EN Journal of Labelled Compounds and Radiopharmaceuticals 2013-07-16

Abstract Background PET radiopharmaceutical development and the implementation of a production method on synthesis module is complex time-intensive task since new methods must be adapted to confines platform in use. Commonly utilized single fluid bus architectures put multiple constraints planning execution, while conventional microfluidic solutions are limited by compatibility at macro-to-micro interface . In this work we introduce ISAR custom-tailored paths leveraging up 70 individually...

10.1186/s41181-019-0077-0 article EN cc-by EJNMMI Radiopharmacy and Chemistry 2019-09-18

10.1016/0007-0971(85)90072-5 article EN British Journal of Diseases of the Chest 1985-01-01

Sarcosine is a known substrate of proton-coupled amino acid transporters (PATs), which are overexpressed in selected tissues and solid tumors. Sarcosine, an <i>N</i>-methyl derivative the glycine metabolic product choline, plays important role for prostate cancer aggressiveness progression. <b>Methods:</b><sup>11</sup>C-radiolabeled sarcosine was tested as new PET imaging probe comparison with <sup>11</sup>C-choline 2 tumor xenograft models (DU-145 PC-3). We characterized...

10.2967/jnumed.116.173179 article EN Journal of Nuclear Medicine 2017-03-16

We recently upgraded our [18F]fludeoxyglucose (FDG) production capabilities with the goal of futureproofing FDG clinical supply, expanding number batches we can manufacture each day, and improving patient throughput in nuclear medicine clinic. In this paper report upgrade synthesis modules to GE FASTLab 2 platform (Phase 1) cyclotron updates 2) from both practical regulatory perspectives. summarize experience manufacturing on module a high-yielding self-shielded niobium (Nb) fluorine-18...

10.1186/s41181-018-0048-x article EN cc-by EJNMMI Radiopharmacy and Chemistry 2018-10-05
Coming Soon ...